Foa R, Fierro M T, Raspadori D, Bonferroni M, Cardona S, Liao X S, Cesano A, Matera L, Gillio Tos A, Tola E
Dipartimento di Scienze Biomediche e Oncologia Umana, University of Torino, Italy.
Bone Marrow Transplant. 1989 Jan;4 Suppl 1:153-5.
Lymphokine activated killer (LAK) cells are being considered as a new and promising form of immunotherapy in the management of patients with solid tumours. Few informations are instead available on these cytotoxic effectors in haematological neoplasias. Here we shall discuss the possible role of LAK cells in human leukaemias. Evidence will be provided for a rationale in the clinical exploitment of Interleukin 2 (IL2)/LAK cells in the treatment of acute leukaemia patients, whilst the implication of these cytotoxic populations appears more uncertain in chronic lymphoproliferative disorders.
淋巴因子激活的杀伤细胞（LAK细胞）被认为是实体瘤患者免疫治疗中一种新的、有前景的形式。相反，关于这些细胞毒性效应细胞在血液系统肿瘤中的信息却很少。在这里，我们将讨论LAK细胞在人类白血病中的可能作用。将提供证据支持白细胞介素2（IL2）/LAK细胞在治疗急性白血病患者中的临床应用原理，而这些细胞毒性群体在慢性淋巴细胞增殖性疾病中的意义似乎更不确定。
